Skip to main content

Clifford Chance

Clifford Chance

News and awards

Clifford Chance advises Medlive Technology's US$540 million Hong Kong IPO

  • en
  • zh
  • Language options

19 July 2021

Clifford Chance advises Medlive Technology's US$540 million Hong Kong IPO

Leading international law firm Clifford Chance has advised the underwriters Goldman Sachs, Haitong International Capital, and China International Capital Corporation (CICC) on the US$540 million initial public offering of Medlive Technology Co., Ltd on the Main Board of Hong Kong Stock Exchange. Goldman Sachs and Haitong International Capital also act as joint sponsors of the IPO.

Established in 2013, Medlive Technology is one of the largest online platforms for medical professionals (physicians, pharmaceutical and medical device companies, hospitals) and patients in China. Medlive Technology provides its participants with a wide spectrum of solutions, including digital healthcare marketing services, patient recruitment service for clinical trials, real-world studies (RWS) solutions, latest clinical references, AI-enabled patient management services and electronic data capture (EDC) system for automated data collection and management.

Partners Christine Xu and Fang Liu co-led the deal with support from senior associates Gehuan Liu, Queenie Tong, Qingqing Bu, Emma Bao and trainee Yumeng Fan.

Christine said, "The successful IPO of Medlive Technology indicates that the demand for initial public offerings in Hong Kong will continue to grow especially in the healthcare and TMT sectors. We are honoured to have supported Medlive Technology in achieving a historic milestone in its development."

The firm's Greater China IPO practice regularly advises on IPOs in the healthcare sector, including Ping An Good Doctor, SciClone Pharmaceuticals and Hygeia Healthcare. The firm has also advised on the IPOs of early-stage biotech companies such as Zylox-Tonbridge Medical Technology, Harbour BioMed and Ascentage Pharma.

高伟绅助力医脉通科技有限公司5.4亿美元香港首次公开发行

国际领先律师事务所高伟绅就医脉通科技有限公司的5.4亿美元首次公开发行和香港联交所上市,为联席保荐人及承销商高盛、海通国际及中金提供法律服务。

医脉通成立于2013年,是一家中国大型在线专业医师平台。截至2020年底,医脉通平台约有350万注册用户,其中约240万用户为执业医师。其他用户包括患者、制药及医疗设备公司。

医脉通为用户提供数字医疗营销服务、临床试验患者招募服务、真实世界研究(“RWS”)支持解决方案、最新医学学习材料及临床实践的场景、AI赋能的智能患者管理服务及电子数据采集(“EDC”)系统。

本项目团队由香港办公室合伙人方刘及许文嘉共同领导,团队成员包括刘戈欢、唐嘉雯、卜青青、包宸及范雨萌。

许文嘉律师表示:“医脉通成功上市反映了医疗资讯平台及相关的科技对香港资本市场的需求日益增加。我们很荣幸能协助医脉通实现企业发展的一个里程碑。”

高伟绅市场领先的大中华区上市业务团队曾为医疗健康企业及平台提供香港首次公开发行法律服务,包括平安好医生赛生药业、时代天使及海吉亚医疗。就涉及香港证券交易所《上市规则》第18A章(适用于发展初期的生物科技公司)之首次公开发行,高伟绅曾为归创通桥和铂医药亚盛医药的香港上市项目提供法律服务。